

Special Issue

Advances in First-Line and Second-Line Treatment Research for Renal Cell Carcinoma

Message from the Guest Editors

Renal cell carcinoma (RCC) represents a biologically heterogeneous malignancy whose management has undergone a profound transformation over the past decade. The introduction of immune checkpoint inhibitors, anti-angiogenic agents, and their rational combinations has reshaped the first-line and second-line therapeutic landscape, leading to significant improvements in survival outcomes across risk groups. Nevertheless, optimal treatment sequencing, resistance mechanisms, patient selection, and real-world applicability remain areas of active investigation and unmet clinical need. In this Special Issue, original research articles, systematic reviews, meta-analyses, and comprehensive reviews are welcome. Topics of interest include, but are not limited to, immunotherapy-based combinations, targeted therapies, sequencing strategies, predictive biomarkers, treatment resistance, toxicity management, and real-world evidence. We look forward to receiving high-quality contributions that will advance clinical decision-making and future research in RCC.

Guest Editors

Dr. Francesco Ditunno

Department of Urology, University of Verona, Verona, Italy

Prof. Dr. Celeste Manfredi

Urology Unit, Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy

Dr. Antonio Franco

Department of Urology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy

Deadline for manuscript submissions

15 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/269012

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)